Noortje Groot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4650955/publications.pdf

Version: 2024-02-01

933447 1125743 14 818 10 13 citations h-index g-index papers 16 16 16 958 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitisâ€"the SHARE initiative. Rheumatology, 2019, 58, 1607-1616.	1.9	165
2	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1788-1796.	0.9	139
3	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1965-1973.	0.9	105
4	European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative. Rheumatology, 2019, 58, 672-682.	1.9	103
5	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides – the SHARE initiative. Rheumatology, 2019, 58, 656-671.	1.9	77
6	European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1637-1641.	0.9	75
7	Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Annals of the Rheumatic Diseases, 2014, 73, 1500-1507.	0.9	56
8	HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know. Pediatric Rheumatology, 2016, 14, 12.	2.1	31
9	Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment. Vaccine, 2017, 35, 2818-2822.	3.8	26
10	Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study. Lupus, 2020, 29, 934-942.	1.6	18
11	MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis. Rheumatology, 2019, 58, 1302-1303.	1.9	11
12	Effects of Childhood-onset Systemic Lupus Erythematosus on Academic Achievements and Employment in Adult Life. Journal of Rheumatology, 2021, 48, 915-923.	2.0	8
13	Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study. Pediatric Rheumatology, 2020, 18, 87.	2.1	4
14	THU0240â€GENE EXPRESSION SIGNATURES ARE RELATED TO SPECIFIC SUBSETS OF PATIENTS WITH SYSTEMI LUPUS ERYTHEMATOSUS. , 2019, , .	С	0